The story of Sildenafil presents a challenging picture for shareholders. While the initial launch generated significant returns, the lapse of its patent opened the door to cheaper versions, dramatically diminishing https://alvingniz662048.csublogs.com/49734636/the-copyright-and-big-pharma-a-precarious-bet